Epidermal Expression of Receptor for Advanced Glycation End Products (RAGE) Is Related to Inflammation and Apoptosis in Human Skin

    November 2015 in “ Experimental Dermatology ”
    Maeko Iwamura, Yasuhiko Yamamoto, Yoshiaki Kitayama, Kazuhiko Higuchi, Tsutomu Fujimura, Tadashi Hase, Hiroshi Yamamoto
    Image of study
    TLDR Skin RAGE levels are linked to inflammation and cell death.
    The study, which analyzed skin samples from 67 patients, found that the expression of the receptor for advanced glycation end products (RAGE) in the human epidermis is significantly correlated with epidermal thickness and is predominantly expressed in keratinocytes, fibroblasts, and endothelial cells. The expression of the AGER gene, responsible for encoding membrane-bound RAGE (mRAGE), was positively associated with levels of pro-inflammatory cytokines and pro-apoptotic factors, indicating its potential role in regulating inflammation and apoptosis in the skin. The findings suggest that mRAGE may be important for maintaining skin homeostasis by monitoring and responding to acute epidermal reactions.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 725 results

      community Binding affinity of pyrilutamide!

      in Update  167 upvotes 2 years ago
      Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

      community AnagenInc says GT20029 is possible now

      in Research/Science  117 upvotes 1 year ago
      AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 8 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

    Similar Research

    5 / 1000+ results